-
A274865-1mgHighly selective D 4 agonist.
-
A274705-5mgAnagrelide (Xagrid) is a Platelet-reducing Agent. The mechanism of action of anagrelide is as a Phosphodiesterase 3 Inhibitor. The physiologic effect of anagrelide is by means of Decreased Platelet Production.
-
A194926-5g4-Amino-2-chloro-3-fluorobenzonitrile.
-
A189097-500gAmmonium dimolybdate.
-
A189097-25gAmmonium dimolybdate.
-
A189097-100gAmmonium dimolybdate.
-
A186203-5g2-Amino-3-cyano-4-methylpyridine.
-
A186203-250mg2-Amino-3-cyano-4-methylpyridine.
-
A186203-10g2-Amino-3-cyano-4-methylpyridine.
-
A177474-5mgAderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large
-
A177474-25mgAderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large
-
A177474-1mgAderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large